Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COR
COR logo

COR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
315.910
Open
314.000
VWAP
311.63
Vol
601.12K
Mkt Cap
60.78B
Low
308.860
Amount
187.33M
EV/EBITDA(TTM)
13.37
Total Shares
194.53M
EV
67.14B
EV/OCF(TTM)
15.65
P/S(TTM)
0.19
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
Show More

Events Timeline

(ET)
2026-03-23
07:10:00
Cencora Acquires EyeSouth Partners' Retina Business for $1.1 Billion
select
2026-03-17 (ET)
2026-03-17
16:40:00
Major Averages Close Fractionally Higher, WTI Crude Near $96
select
2026-03-17
11:50:00
Major Averages Broadly Higher at Noon, Oil Prices Rise Again
select
2026-03-17
09:20:00
Cencora Reaffirms FY 2026 Adjusted EPS Guidance
select
2026-03-17
09:20:00
Cencora CFO James Cleary to Retire on June 30
select

News

seekingalpha
8.5
03-24seekingalpha
Cencora Acquires EyeSouth's Retina Business for $1.1B
  • Acquisition Overview: Cencora (COR) has signed an agreement to acquire EyeSouth Partners' retina business for $1.1 billion through its eye care subsidiary, Retina Consultants of America, marking a significant move in its ongoing M&A strategy aimed at strengthening its market position in the ophthalmology sector.
  • Financial Impact Analysis: The company anticipates that the transaction, after adjusting for financing costs, will slightly boost its adjusted diluted earnings per share (EPS) in the first twelve months post-closure, indicating confidence in its future financial performance.
  • Accelerated M&A Activity: Cencora has ramped up its M&A activities recently, with this acquisition following a $3.5 billion merger agreement with Covetrus involving its MWI Animal Health unit, highlighting its aggressive expansion strategy within the healthcare industry.
  • Future Outlook: While Cencora reaffirmed its fiscal 2026 outlook, it noted that the deal is not expected to close within the current fiscal year, reflecting a cautious approach to integration amid its aggressive acquisition strategy.
Marketbeat
3.0
03-23Marketbeat
Active ETFs Outperform Passive Ones, with These Leading the Way
  • Active vs. Passive ETFs: Active ETFs, which are managed by fund managers and not tied to specific indices, have seen a significant increase in fees and performance compared to traditional passive ETFs, with active funds outperforming passive ones in recent years.

  • Capital Group Dividend Value ETF (CGDV): CGDV aims to provide dividend income exceeding the average yield on U.S. stocks, focusing on established domestic firms and diversifying across various sectors, with a strong emphasis on stability and income generation.

  • T. Rowe Price Capital Appreciation ETF (TCAF): TCAF combines well-known stocks with lesser-known companies, targeting growth at reasonable prices, and aims to deliver strong returns with lower risk compared to the broader market.

  • Dan Ives' AI Revolution ETF (IVES): This ETF, managed by a well-known technology analyst, focuses on AI-related companies and offers investors access to a curated selection of stocks in the tech space, appealing to those interested in the growing AI sector.

Newsfilter
8.5
03-23Newsfilter
Cencora Reaffirms Fiscal 2026 Financial Guidance Amid $1.1 Billion Acquisition
  • Acquisition Agreement: Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion, which will integrate EyeSouth's retina physicians into Cencora's Retina Consultants of America, thereby enhancing its market position in ophthalmology.
  • Financial Impact: Cencora expects the acquisition to be slightly accretive to its adjusted diluted EPS in the first twelve months post-transaction, although the deal's completion is not included in its fiscal 2026 financial guidance.
  • Strategic Collaboration: The partnership with EyeSouth will enhance access to innovative treatments, as EyeSouth's physicians will leverage RCA's clinical trial and research resources to further improve patient care quality.
  • Advisory Team: BofA Securities and Citi are serving as financial advisors to Cencora, while Sidley Austin LLP acts as legal counsel; Jefferies LLC and Kirkland & Ellis LLP are advising EyeSouth, ensuring a smooth transaction process.
moomoo
8.5
03-23moomoo
CENCORA Acquires EyeSouth Partners' Retina Division for $1.1 Billion
  • Acquisition Announcement: Cencora has announced its intention to acquire EyeSouth Partners' retina business for $1.1 billion.

  • Strategic Move: This acquisition is part of Cencora's strategy to expand its portfolio in the healthcare sector, particularly in eye care services.

NASDAQ.COM
2.0
03-18NASDAQ.COM
Cencora Inc Shares Show Oversold Signal
  • Oversold Indicator: Cencora Inc (Ticker: COR) hit an RSI of 29.9 during Wednesday's trading, indicating an oversold condition with shares dropping to a low of $318.12, suggesting that the recent heavy selling pressure may be waning, thus providing potential buying opportunities for investors.
  • Market Comparison: Compared to the current RSI of 36.3 for the S&P 500 ETF (SPY), COR's oversold status may attract bullish investors looking for entry points to capitalize on a potential rebound in the stock price.
  • Price Fluctuation: COR's 52-week low stands at $262.73, while the high is $377.54, with the last trade at $325.18, indicating the stock's performance within this range, which could influence investor decisions moving forward.
  • Investor Sentiment: As COR shares enter oversold territory, investors may reassess their strategies and consider buying in anticipation of a price recovery, potentially profiting from future market rebounds.
NASDAQ.COM
4.5
03-17NASDAQ.COM
US Stocks Rise Slightly Amid Oil Price Surge
  • Market Performance: The S&P 500 Index rose by 0.25%, the Dow Jones Industrial Average increased by 0.10%, and the Nasdaq 100 Index climbed by 0.51%, reflecting strong performances from chipmakers and travel stocks, despite signs of a slowdown in hiring impacting market sentiment.
  • Oil Price Surge: WTI crude oil prices jumped over 2% due to renewed Iranian attacks on key energy infrastructure, leading to expectations of an 8 million bpd reduction in global oil supply this month, which adds to market uncertainty and inflation concerns.
  • Fed Policy Expectations: The market anticipates that the Federal Reserve will keep the federal funds target range unchanged at the upcoming FOMC meeting, even as the core PCE price index remains above target levels, indicating persistent inflationary pressures.
  • Airline Stock Recovery: Delta Air Lines saw its stock rise over 6% after raising its Q1 revenue forecast, indicating signs of recovery in the airline sector amid rising fuel costs, with travel and hotel stocks also benefiting from increased bookings.
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
Wall Street analysts forecast COR stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
400.00
Averages
415.38
High
440.00
Current: 0.000
sliders
Low
400.00
Averages
415.38
High
440.00
BofA
Allen Lutz
Neutral
maintain
$360 -> $380
AI Analysis
2026-03-06
Reason
BofA
Allen Lutz
Price Target
$360 -> $380
AI Analysis
2026-03-06
maintain
Neutral
Reason
BofA analyst Allen Lutz raised the firm's price target on Cencora (COR) to $380 from $360 and keeps a Neutral rating on the shares. McKesson (MCK) "quietly" received a new National Drug Code for a biosimilar version of Neulasta a few weeks ago and while investors may be skeptical of McKesson's ambitions here, the firm frames "why this initial investor reaction could be wrong" based on seven large biosimilars coming to market over the next few years, including four that are directly addressable. The firm raised its McKesson target to reflect optionality on co-manufacturing and raised its Cencora (COR) target as well to reflect similar optionality.
Barclays
NULL -> Overweight
maintain
$400 -> $425
2026-02-13
Reason
Barclays
Price Target
$400 -> $425
2026-02-13
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Cencora to $425 from $400 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 19.33, compared to its 5-year average forward P/E of 14.70. For a more detailed relative valuation and DCF analysis to assess Cencora Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
14.70
Current PE
19.33
Overvalued PE
16.99
Undervalued PE
12.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.82
Current EV/EBITDA
13.79
Overvalued EV/EBITDA
12.44
Undervalued EV/EBITDA
9.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.14
Current PS
0.19
Overvalued PS
0.16
Undervalued PS
0.12

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top stocks in health sector
Intellectia · 38 candidates
Market Cap: >= 10.00BSector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, Healthcare Equipment & Supplies, Healthcare Providers & Services, PharmaceuticalsAnalyst Consensus: Strong Buy, Moderate BuyRevenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEReturn On Equity: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
866.87B
ABBV logo
ABBV
AbbVie Inc
364.65B
AZN logo
AZN
AstraZeneca PLC
293.00B
MRK logo
MRK
Merck & Co Inc
282.35B
UNH logo
UNH
UnitedHealth Group Inc
254.55B
AMGN logo
AMGN
Amgen Inc
188.63B
run based on daily
Intellectia · 80 candidates
Ticker
Name
Market Cap$
top bottom
SPOT logo
SPOT
Spotify Technology SA
103.40B
COR logo
COR
Cencora Inc
68.24B
AFL logo
AFL
Aflac Inc
56.90B
MSCI logo
MSCI
MSCI Inc
44.25B
ONC logo
ONC
BeOne Medicines AG
40.49B
ED logo
ED
Consolidated Edison Inc
37.48B

Whales Holding COR

P
Pacer Advisors, Inc.
Holding
COR
+6.82%
3M Return
B
Blackstone Inc.
Holding
COR
+6.09%
3M Return
B
Boston Partners Global Investors, Inc.
Holding
COR
+4.98%
3M Return
S
Scout Investments, Inc.
Holding
COR
+3.76%
3M Return
D
Dakota Wealth, LLC
Holding
COR
+3.18%
3M Return
J
Jefferies Financial Group Inc.
Holding
COR
+1.54%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cencora Inc (COR) stock price today?

The current price of COR is 310.12 USD — it has decreased -0.75

What is Cencora Inc (COR)'s business?

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

What is the price predicton of COR Stock?

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is415.38 USD with a low forecast of 400.00 USD and a high forecast of 440.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cencora Inc (COR)'s revenue for the last quarter?

Cencora Inc revenue for the last quarter amounts to 85.93B USD, increased 5.45

What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?

Cencora Inc. EPS for the last quarter amounts to 2.87 USD, increased 14.80

How many employees does Cencora Inc (COR). have?

Cencora Inc (COR) has 51000 emplpoyees as of March 31 2026.

What is Cencora Inc (COR) market cap?

Today COR has the market capitalization of 60.78B USD.